Published in J Mol Med (Berl) on November 22, 2012
Study of FG-3019 in Subjects With Type 2 DM and KD on ACEi and/or ARB Therapy | NCT00913393
Emerging role of HMGB1 in fibrotic diseases. J Cell Mol Med (2014) 0.94
Matrix Producing Cells in Chronic Kidney Disease: Origin, Regulation, and Activation. Curr Pathobiol Rep (2013) 0.92
Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy. Curr Med Chem (2015) 0.89
Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol (2016) 0.85
Mathematical model of renal interstitial fibrosis. Proc Natl Acad Sci U S A (2014) 0.85
Autophagy, Innate Immunity and Tissue Repair in Acute Kidney Injury. Int J Mol Sci (2016) 0.84
TGF-β regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes. Virology (2013) 0.83
Involvement of endoplasmic reticulum stress in angiotensin II-induced NLRP3 inflammasome activation in human renal proximal tubular cells in vitro. Acta Pharmacol Sin (2015) 0.81
Glycogen synthase kinase-3 inhibition attenuates fibroblast activation and development of fibrosis following renal ischemia-reperfusion in mice. Dis Model Mech (2015) 0.78
Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice. Drug Des Devel Ther (2017) 0.77
Application of Wnt Pathway Inhibitor Delivering Scaffold for Inhibiting Fibrosis in Urethra Strictures: In Vitro and in Vivo Study. Int J Mol Sci (2015) 0.77
Role of HIPK2 in kidney fibrosis. Kidney Int Suppl (2011) (2014) 0.77
Genomic Analysis of Kidney Allograft Injury Identifies Hematopoietic Cell Kinase as a Key Driver of Renal Fibrosis. J Am Soc Nephrol (2016) 0.75
RelA/p65 inhibition prevents tendon adhesion by modulating inflammation, cell proliferation, and apoptosis. Cell Death Dis (2017) 0.75
Transcriptome analysis reveals manifold mechanisms of cyst development in ADPKD. Hum Genomics (2016) 0.75
Stop chronic kidney disease progression: Time is approaching. World J Nephrol (2016) 0.75
HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease. Front Physiol (2015) 0.75
Epithelial Plasticity versus EMT in Kidney Fibrosis. Trends Mol Med (2015) 0.75
Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease. Am J Physiol Renal Physiol (2013) 0.75
Mouse chromosome 2 harbors genetic determinants of resistance to podocyte injury and renal tubulointerstitial fibrosis. BMC Genet (2016) 0.75
Novel Therapeutics Identification for Fibrosis in Renal Allograft Using Integrative Informatics Approach. Sci Rep (2017) 0.75
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
The inflammasomes. Cell (2010) 19.37
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
TGF-beta signaling and the fibrotic response. FASEB J (2004) 9.81
Transforming growth factor beta in tissue fibrosis. N Engl J Med (1994) 9.73
Controlling TGF-beta signaling. Genes Dev (2000) 8.13
Mechanism of activation of the TGF-beta receptor. Nature (1994) 8.10
Regulation of immune responses by TGF-beta. Annu Rev Immunol (1998) 8.01
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Nonresolving inflammation. Cell (2010) 7.74
Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell (2000) 6.69
Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol (2008) 5.83
Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol (2008) 5.06
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A (2007) 4.92
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature (1990) 4.64
Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol (2002) 4.14
Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature (1992) 3.96
Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev (1997) 3.86
New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol (2009) 3.83
Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol (2010) 3.75
Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis (1992) 3.73
Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol (2011) 3.68
Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A (2000) 3.48
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol (2009) 3.42
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16
Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev (2004) 3.14
Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int (2007) 3.09
MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J (2008) 2.75
NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med (1997) 2.66
TGF-beta in renal injury and disease. Semin Nephrol (2007) 2.65
Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med (2005) 2.61
Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res (2006) 2.59
Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int J Biol Sci (2011) 2.59
Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol (2010) 2.55
Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int (2009) 2.53
miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol (2010) 2.51
Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol (2010) 2.45
Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat Med (2012) 2.44
Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? J Clin Invest (2011) 2.43
Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes (1996) 2.42
Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest (2010) 2.42
Expression of connective tissue growth factor in human renal fibrosis. Kidney Int (1998) 2.19
Pirfenidone for diabetic nephropathy. J Am Soc Nephrol (2011) 2.04
NF-kappaB in renal inflammation. J Am Soc Nephrol (2010) 2.00
Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol Ther (2001) 1.95
Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension (2010) 1.94
Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J (2003) 1.93
Angiotensin II and renal fibrosis. Hypertension (2001) 1.87
E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes (2010) 1.85
Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension (2009) 1.85
Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol (2010) 1.84
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med (2012) 1.83
Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int (2010) 1.83
Toward a unified theory of renal progression. Annu Rev Med (2006) 1.81
Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2007) 1.80
Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem Cell Biol (2008) 1.77
Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol (2009) 1.76
Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int (1999) 1.76
Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells (2009) 1.71
Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol (2004) 1.70
Aldosterone activates NF-kappaB in the collecting duct. J Am Soc Nephrol (2008) 1.67
Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol (2004) 1.64
EGFR signaling promotes TGFβ-dependent renal fibrosis. J Am Soc Nephrol (2011) 1.64
Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J (2007) 1.62
Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis. J Am Soc Nephrol (2011) 1.62
Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair (2011) 1.61
Diabetes complications: the microRNA perspective. Diabetes (2011) 1.60
Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol (2004) 1.55
Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells. J Mol Med (Berl) (1999) 1.54
Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood (1996) 1.51
TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol (2008) 1.49
Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol (2009) 1.45
Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol (2005) 1.45
Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. Front Biosci (2008) 1.44
Post-transcriptional up-regulation of Tsc-22 by Ybx1, a target of miR-216a, mediates TGF-{beta}-induced collagen expression in kidney cells. J Biol Chem (2010) 1.42
Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest (1993) 1.40
Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol (2003) 1.39
Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant (2007) 1.37
Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol (2002) 1.36
Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol (2005) 1.35
HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle (2007) 1.34
Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate. Clin Nephrol (1981) 1.30
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol (2010) 1.30
Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol (2009) 1.29
Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int (2010) 1.27
Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol (2011) 1.26
MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett (2009) 1.22
Angiotensin II as a pro-inflammatory mediator. Curr Opin Investig Drugs (2002) 1.19
Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J Am Soc Nephrol (2012) 1.19
Treatment targets in renal fibrosis. Nephrol Dial Transplant (2007) 1.19
Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific protein-1 (FSP-1) in inflammatory renal disease. Kidney Int (2005) 1.17
Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis (2009) 1.17
Fibrocytes: a new insight into kidney fibrosis. Kidney Int (2007) 1.16
Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int (2000) 1.15
Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol (2004) 1.15
Toll-like receptors: emerging concepts in kidney disease. Curr Opin Nephrol Hypertens (2007) 1.15
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Role of the retinoic acid receptor-α in HIV-associated nephropathy. Kidney Int (2010) 1.89
Krüppel-like factor 6 regulates mitochondrial function in the kidney. J Clin Invest (2015) 1.72
Reduction of Stat3 activity attenuates HIV-induced kidney injury. J Am Soc Nephrol (2009) 1.70
Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol (2008) 1.56
Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A (2006) 1.32
Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One (2011) 1.24
Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol (2008) 1.22
Kruppel-like factor 15 (KLF15) is a key regulator of podocyte differentiation. J Biol Chem (2012) 1.21
Signaling in regulation of podocyte phenotypes. Nephron Physiol (2009) 1.13
Successful medical management of emphysematous gastritis with concomitant portal venous air: a case report. J Med Case Rep (2010) 1.10
HIV-associated nephropathy: pathogenesis. Curr Opin Nephrol Hypertens (2011) 1.07
Expression of HIV transgene aggravates kidney injury in diabetic mice. Kidney Int (2013) 1.00
JAK/STAT signaling in renal diseases. Kidney Int (2010) 0.95
HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. AIDS (2010) 0.92
Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure. Kidney Int (2012) 0.91
Up-regulation of the homophilic adhesion molecule sidekick-1 in podocytes contributes to glomerulosclerosis. J Biol Chem (2010) 0.91
Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis. Kidney Int (2013) 0.90
Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. J Clin Invest (2014) 0.89
Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. AIDS (2013) 0.88
Podocyte-specific RAP1GAP expression contributes to focal segmental glomerulosclerosis-associated glomerular injury. J Clin Invest (2014) 0.87
Protein kinase target discovery from genome-wide messenger RNA expression profiling. Mt Sinai J Med (2010) 0.87
The primary glomerulonephritides: a systems biology approach. Nat Rev Nephrol (2013) 0.82
Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Am J Physiol Renal Physiol (2014) 0.82
The burden of dialysis-requiring acute kidney injury among hospitalized adults with HIV infection: a nationwide inpatient sample analysis. AIDS (2015) 0.78
A new mechanism for albuminuria-induced podocyte injury. J Am Soc Nephrol (2013) 0.78
Hepatitis C virus infection among patients with non-Hodgkin's lymphoma in northern India. Hepatol Int (2011) 0.77
Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients. Semin Dial (2012) 0.76
Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease. Am J Physiol Renal Physiol (2013) 0.75
Thiazides for hypervolemic hypernatremia: a valid therapeutic strategy? Am J Kidney Dis (2013) 0.75
Capturing the in vivo molecular signature of the podocyte. Kidney Int (2013) 0.75
Ortner syndrome in an elderly vasculopath. South Med J (2008) 0.75
The use of vasopressin receptor antagonists in hyponatremia. Curr Opin Investig Drugs (2010) 0.75
Haemopericardium in blue rubber bleb naevus syndrome (Bean syndrome). Med J Aust (2008) 0.75
Erratum: RTN1 mediates progression of kidney disease by inducing ER stress. Nat Commun (2015) 0.75
Absent circadian rhythm of proteinuria in hospitalized patients with preeclampsia. Hypertens Pregnancy (2010) 0.75